Exelixis EXEL
Exelixis is a US biopharmaceutical company focused on developing and commercializing oncology therapies, whose main product is cabozantinib, a kinase inhibitor approved for several types of cancer. Exelixis shows solid financial health (net cash, DN/EBITDA -0.66) and exceptional quality (ROE 44.39%, gross margin 96.48%), with revenue growth of 10.6% and earnings growth of 26.2%. However, the FDA delay for zanzalintinib introduces uncertainty about the timeline of a key product, moderating short-term growth expectations.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Exelixis is a US biopharmaceutical company focused on developing and commercializing oncology therapies, whose main product is cabozantinib, a kinase inhibitor approved for several types of cancer. Exelixis shows solid financial health (net cash, DN/EBITDA -0.66) and exceptional quality (ROE 44.39%, gross margin 96.48%), with revenue growth of 10.6% and earnings growth of 26.2%. However, the FDA delay for zanzalintinib introduces uncertainty about the timeline of a key product, moderating short-term growth expectations.
Score by category
| Category | Score |
|---|---|
| Financial health | 9.0 |
| Quality / Moat | 9.4 |
| Valuation | 5.9 |
| Growth | 7.2 |
| Dividend | 1.5 |
| Momentum | 7.3 |
| Risk & Context | 8.2 |
OVERALL SCORE: 7.4/10
Context and risks
Specific regulatory risk: the FDA review extension for zanzalintinib introduces uncertainty about the launch timeline of a key product. Additionally, dependence on cabozantinib as the main revenue source concentrates risk on the approval of new drugs.
News considered in the analysis
- Exelixis (EXEL) Gets FDA Review Extension For Zanzalintinib to metastatic Colorectal Cancer — La extensión de la revisión de la FDA retrasa el lanzamiento de un activo clave, pero la aprobación sigue siendo probable.
- Exelixis Eyes Oncology Deals, Readies Zanzalintinib Launch as Cabozantinib Tops $3B — El crecimiento de cabozantinib y la preparación para el lanzamiento de zanzalintinib son positivos, aunque la actividad de acuerdos es incierta.
- Exelixis (EXEL) Faces a Three-Month Zanzalintinib Review Extension. Can the Data Support Approval? — La extensión de tres meses genera incertidumbre sobre el calendario, pero no sobre la eficacia del fármaco.
- Could Zanzalintinib's FDA Delay Affect Exelixis' Growth Plans? — El retraso regulatorio podría afectar las proyecciones de crecimiento a corto plazo, pero el impacto es moderado.
- Alpha Teknova (TKNO) Moves 7.1% Higher: Will This Strength Last? — Noticia sobre otra empresa sin relevancia para Exelixis.
Verdict: Hold, with attention to the regulatory evolution of zanzalintinib and the company's ability to diversify beyond cabozantinib.
Main risk: Dependence on cabozantinib as the main revenue source and the delay in zanzalintinib's approval, which concentrate risk on the success of the pipeline.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →